Semaglutide reduces risk for major adverse cardiovascular events in patients with obesity and heart failure
by Elana GotkineSemaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or obesity and hear
Updated on: September 05,2024
0

Semaglutide reduces risk for major adverse cardiovascular events in patients with obesity and heart failure
by Elana GotkineSemaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or obesity and hear
Updated on:September 05,2024
0
